Canaccord analyst Whitney Ijem initiated coverage of Sigilon Therapeutics with a Buy rating and $6 price target. While Sigilon has had a rough couple of years with its proprietary pipeline, its cell therapy approach for type 1 diabetes is worth a look following recent "encouraging" initial preclinical data, Ijem tells investors in a research note.
Published first on TheFly
